Hal Sreden, MD
Pulmonary Disease · Brunswick, MENPI 1467555789
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,477 of the $5,306 with a category attached, or 65.5%. 30 manufacturers reported payments, led by Olympus Corporation Of The Americas at 34.2% of the total.
Across 187 payments — averaging $28.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$2K
- GSK$812
- Grifols USA, LLC$438
- Sanofi$303
- AstraZeneca$208
- Mallinckrodt Hospital Products Inc.$188
- plus $2K from 24 others
What the payments were for
- Travel & lodging$1,70532%
- Food & beverage$3,47766%
- Education$1242%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 12 | $1,815 |
| GSK | 59 | $812 |
| Grifols USA, LLC | 21 | $438 |
| Sanofi | 13 | $303 |
| AstraZeneca | 7 | $208 |
| Mallinckrodt Hospital Products Inc. | 2 | $188 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $168 |
| AbbVie(2 entities) | 7 | $141 |
| Paratek Pharmaceuticals, Inc. | 2 | $139 |
| Actelion Pharmaceuticals US, Inc. | 3 | $124 |
| Regeneron Healthcare Solutions, Inc. | 6 | $116 |
| Insmed, Inc. | 4 | $91 |
| Mylan Specialty L.p. | 3 | $77 |
| La Jolla Pharmaceutical Company | 4 | $69 |
| Merck | 4 | $66 |
| Vifor Pharma, Inc. | 3 | $65 |
| Gilead | 5 | $64 |
| Baxter Healthcare | 2 | $52 |
| Philips North America LLC | 4 | $52 |
| Electromed, Inc. | 4 | $45 |
| Verona Pharma, Inc. | 3 | $45 |
| Boehringer Ingelheim | 2 | $41 |
| Johnson & Johnson | 1 | $39 |
| United Therapeutics Corporation | 2 | $36 |
| Masimo Corporation | 1 | $26 |
| Viatris Specialty LLC | 1 | $24 |
| Novartis | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Siemens Medical Solutions USA, Inc. | 1 | $14 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,306 in reported general payments places this provider in the 85th percentile of 58 pulmonary disease providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Brunswick
- Donald WoloszynBrunswick$4K
- Alison WellsBrunswick$159
- Vu HoBrunswick$66
- James McCormickBrunswick$63
- Caitlin WelchBrunswick$38
- Patrick KeaneyBrunswick$15
- Jonathan EvansSouth Portland$322K
- Andrew FildermanRockport$210K
- Andrew DixonBangor$40K
- Meagan MooreSouth Portland$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.